Pulse Biosciences (NASDAQ:PLSE) Raised to Sell at StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a research report sent to investors on Tuesday morning.

Pulse Biosciences Trading Down 2.7 %

NASDAQ:PLSE opened at $16.64 on Tuesday. The company has a fifty day moving average price of $17.34 and a 200 day moving average price of $15.01. Pulse Biosciences has a one year low of $5.97 and a one year high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter in the previous year, the company earned ($0.19) EPS.

Institutional Trading of Pulse Biosciences

Institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in shares of Pulse Biosciences by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock valued at $8,020,000 after purchasing an additional 33,200 shares in the last quarter. Barclays PLC lifted its holdings in Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock valued at $530,000 after purchasing an additional 23,738 shares during the last quarter. State Street Corp lifted its holdings in Pulse Biosciences by 17.8% during the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after purchasing an additional 69,696 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Pulse Biosciences in the third quarter valued at about $588,000. Finally, Charles Schwab Investment Management Inc. grew its stake in Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after buying an additional 97,565 shares during the last quarter. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.